Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target inhibitory molecules,
such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death …

Methods This study used data from an oncologic clinical trial of adaptive dosing combination
ICI therapy in patients with advanced melanoma. Plasma was collected at baseline and 6 …

Background Immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs)
are sometimes associated with autoantibodies, but we do not know how frequently or …

Objective We performed a systematic literature review to identify all reports of immune
checkpoint inhibitor–associated inflammatory arthritis to describe it phenotypically and …

Immune checkpoint inhibitor (ICI) therapies used to treat cancer, such as anti–PD-1
antibodies, can induce autoimmune conditions in some individuals. The T cell mechanisms …

Background Immune checkpoint inhibitors (ICI) can potentially cause ICI-inflammatory arthritis
(ICI-IA), which often resembles rheumatoid arthritis (RA). In this study, we examined the …

In this review, we draw from observational studies, treatment guidelines and our own clinical
experience to describe approaches to monitoring and management of immune checkpoint …

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can result in
toxicities, known as immune-related adverse events (irAEs), due to a hyperactivated immune …

Background Interstitial lung disease is a known complication of rheumatoid arthritis, with a
lifetime risk of developing the disease in any individual of 7·7%. We aimed to assess the safety…

Objective To develop initial American College of Rheumatology (ACR) guidelines on the
use of exercise, rehabilitation, diet, and additional interventions in conjunction with disease‐…